They will be members of the Executive Board of DZIF for further three years: Prof Dirk Heinz, Prof Ulrike Protzer und Prof Martin Krönke (from left). The General Assembly of DZIF decided this unanimously in Munich.
Welcome to DZIF
It is the 21st century and infections are still a major challenge for medicine. What is our recourse as germs become increasingly resistant to antibiotics? What can we do to prevent the spread of a pathogen? The researchers at the German Center for Infection Research (DZIF) are tackling these and many other issues.
Drug design against bacterial biofilms
Alexander Titz and his team from the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) develop substances that target this bacterial protective wall.
HIPS: A new building for pharmaceutical research
DZIF Chairman Martin Krönke and Rolf Müller, Director of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), are pleased: The new HIPS building offers additional space for drug development. The Institute in Saarbrücken plays an important role in the development of new antibiotics at the German Center for Infection Research.
26 November 2015 - PRESS RELEASE
His aim is to develop a vaccine against the widespread gastric pathogen Helicobacter pylori: for his work in this field, Professor Markus Gerhard, Technische Universität München (TUM), was awarded the DZIF Prize for Translational Infection Research. The prize, worth 5000 euros, was awarded at the German Center for Infection Research (DZIF) Annual Meeting in Munich. [ more ]
25 November 2015 - PRESS RELEASE
11 November 2015 - PRESS RELEASE
DZIF e. V. – Inhoffenstraße 7, 38124 Braunschweig, Germany
PHONE +49 531-6181 1152 EMAIL firstname.lastname@example.org